바이오테크 보도자료
-
- Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
- Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset i...
- 2021년 04월 13일
-
- Diaceutics Appoints Yvanka Gilliam as Vice President of Operations, Asia Pacific
- Diaceutics PLC, (AIM: DXRX), today announces the appointment of Yvanka Gilliam as Vice President of Operations, Asia Pacific (APAC). In her new role, Yvanka will be responsible for managing business development and operations within the APAC regio...
- 2021년 04월 13일
-
- Yokogawa Selects C3 AI Suite to Enhance Enterprise AI Applications
- C3 AI (NYSE: AI) and Yokogawa Electric Corporation (TOKYO: 6841) (“Yokogawa”) today announced that Yokogawa has selected the C3 AI® Suite as a platform to enhance enterprise AI applications and complement its digital transformation solutions and s...
- 2021년 04월 13일
-
- Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models
- Deargen, an artificial intelligence (AI)-based drug discovery and development biotech company, announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference and Le...
- 2021년 04월 13일
-
- Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
- Humanigen, Inc. (Nasdaq:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced positive results from the Phas...
- 2021년 04월 12일
-
- Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of Nemolizumab in Clinical Trial Subjects With Uncontrolled Atopic Dermatitis
- Galderma today announced that the Journal of the European Academy of Dermatology and Venereology (JEADV) has published full results from a post-hoc analysis of the phase 2b study of its investigational therapy, nemolizumab, in adult patients with ...
- 2021년 04월 08일
-
- Milestone Study Shows Natural Molecule, Urolithin A, Can Improve Muscle Function and Life Expectancy in Mice With Muscle Dystrophy
- Progression of Duchenne Muscle Dystrophy (DMD) can be delayed in mice by supplementing their diets with Urolithin A, according to new results reported today. The findings, published in Science Translational Medicine, raise hopes that new treatment...
- 2021년 04월 08일
-
- Humanigen Announces Closing of Public Offering of Common Stock
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that on April 5,...
- 2021년 04월 07일
-
- NuScale Power Secures $40 Million Investment, Support for SMR Deployment from JGC Holdings Corporation
- NuScale Power today announced that it has finalized an investment and strategic partnership agreement with JGC Holdings Corporation (JGC HD), a holding company of the world's leading EPC contractor group companies headquartered in Japan. As part o...
- 2021년 04월 06일
-
- CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
- The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Nat...
- 2021년 04월 05일
-
- Takeda Hosts Wave 1 Pipeline Market Call
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME...
- 2021년 04월 01일
-
- Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for a total value of up to $670 million USD. The po...
- 2021년 04월 01일
전시회
